Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRHR1 | P34998 | 14/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 1.00 |
| ▸ | FPR3 | P25089 | 2/20 | 0.67 |
| ▸ | TSPO | P30536 | 2/20 | 0.67 |
| ▸ | TMEM97 | Q5BJF2 | 2/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Antalarmin SCHEMBL29832078 | 1.00 | CRHR1 (1.00) | CRHR1TDP1FPR3TSPOTMEM97 | |
| Antalarmin SCHEMBL25395568 | 0.99 | CRHR1 (0.98) | CRHR1TDP1FPR3TSPOTMEM97 | |
| Antalarmin SCHEMBL29601552 | 0.99 | CRHR1 (0.98) | CRHR1TDP1FPR3TSPOTMEM97 | |
| SCHEMBL8617375 | 0.82 | CRHR1 (1.00) | CRHR1TDP1FPR3TSPOTMEM97 | |
| SCHEMBL7965099 | 0.82 | CRHR1 (1.00) | CRHR1TDP1FPR3TSPOTMEM97 | |
| Cp-154526 SCHEMBL29706373 | 0.81 | CRHR1 (1.00) | CRHR1TDP1FPR3TSPOTMEM97 | |
| SCHEMBL8999349 | 0.81 | CRHR1 (0.67) | CRHR1TDP1FPR3TSPOTMEM97 | |
| SCHEMBL5845873 | 0.81 | CRHR1 (0.69) | CRHR1TDP1FPR3TSPOTMEM97 | |
| Cp-154526 SCHEMBL5707848 | 0.81 | CRHR1 (1.00) | CRHR1TDP1FPR3TSPOTMEM97 | |
| Cp-154526 SCHEMBL31012286 | 0.80 | CRHR1 (1.00) | CRHR1TDP1FPR3TSPOTMEM97 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 791 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4450070-A1 | CRF1 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF CONGENITAL ADRENAL HYPERPLASIA | NEUROCRINE BIOSCIENCES, INC. (US) | 2024-10-23 | — | — | EP | claimed |
| US-20210207199-A1 | Genetic Predictors of a Response to Treatment with CRHR1 Antagonists | HMNC Holding GmbH (DE) | 2021-07-08 | — | — | US | claimed |
| US-10729693-B2 | Compositions and methods for the treatment of endometriosis | PONCE MEDICAL SCHOOL FOUNDATION, INC. (US) | 2020-08-04 | — | — | US | claimed |
| CN-111228274-A | CRF for treating congenital adrenal hyperplasia1Receptor antagonists | 纽罗克里生物科学有限公司 | 2020-06-05 | — | — | CN | claimed |
| CN-110403942-A | Prevent and treat the composition and method of habituation | OMEROS CORP | 2019-11-05 | — | — | CN | claimed |
| CN-105250285-B | Prevent and treat the composition and method of habituation | 奥默罗斯公司 | 2019-09-06 | — | — | CN | claimed |
| US-20190269686-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF ENDOMETRIOSIS | PONCE MEDICAL SCHOOL FOUNDATION, INC. (PR) | 2019-09-05 | — | — | US | claimed |
| EP-3277835-B1 | GENETIC PREDICTORS OF A RESPONSE TO TREATMENT WITH CRHR1 ANTAGONISTS | HMNC VALUE GMBH (DE) | 2019-01-09 | — | — | EP | claimed |
| US-20180355430-A1 | Genetic Predictors of a Response to Treatment with CRHR1 Antagonists | HMNC Diagnostics GmbH (DE) | 2018-12-13 | — | — | US | claimed |
| US-10064850-B2 | Compositions and methods for prophylaxis and treatment of addictions | OMEROS CORPORATION (US) | 2018-09-04 | — | — | US | claimed |
| EP-1059100-A2 | Combinations of CRF antagonists and renin-angiotensin system inhibitors | Pfizer Products Inc. (US) | 2000-12-13 | — | — | EP | claimed |
| EP-1040831-A2 | Use of corticotropin releasing factor (CRF) antagonists to prevent sudden death | Pfizer Products Inc. (US) | 2000-10-04 | — | — | EP | claimed |
| US-6051578-A | Pyrazolopyrimidines for treatment of CNS disorders | PFIZER INC. (US) | 2000-04-18 | — | — | US | claimed |
| EP-0674641-B1 | PYRROLOPYRIMIDINES AS CRF ANTAGONISTS | PFIZER (US) | 1999-03-03 | — | — | EP | claimed |
| US-5646152-A | Methods of administering CRF antagonists | PFIZER INC. (US) | 1997-07-08 | — | — | US | claimed |
| EP-0773023-A1 | New uses for corticotropin releasing factor (CRF) antagonists | PFIZER INC. (US) | 1997-05-14 | — | — | EP | claimed |
| EP-0729758-A2 | Pyrazolopyrimidines and pyrrolopyrimidines for treatment of neuronal and other disorders | PFIZER INC. (US) | 1996-09-04 | — | — | EP | claimed |
| EP-0691128-A1 | Methods of administering CRF antagonists | PFIZER INC. (US) | 1996-01-10 | — | — | EP | claimed |
| EP-0674641-A1 | PYRROLOPYRIMIDINES AS CRF ANTAGONISTS | PFIZER INC. (US) | 1995-10-04 | — | — | EP | claimed |
| WO-1994013676-A1 | PYRROLOPYRIMIDINES AS CRF ANTAGONISTS | PFIZER INC. (US) | 1994-06-23 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10064850-B2 | Compositions and methods for prophylaxis and treatment of addictions | OPRK1, OPRL1, OPRD1 | CRHR1 129/4885TDP1 2471/4885FPR3 1225/4885 |
| US-20210207199-A1 | Genetic Predictors of a Response to Treatment with CRHR1 Antagonists | CRHR1, CRHR2, CRH | CRHR1 1/4885TDP1 1468/4885FPR3 125/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.